Sunday, January 3, 2021

REGN-COV2 (Regeneron)

REBEL EM - January 02, 2020 - By Anand Swaminathan
Paper: Weinreich DM et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. NEJM 2020. PMID: 33332778 Free Link Clinical Trials Listing
"Clinical Question: Does REGN-COV2 reduce viral loads, lead to improvements and reduce medical attendance in outpatients with COVID19?
Author Conclusion: “In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”
Our Conclusions: No conclusions can be drawn from a study published with no hypothesis. Our stance is that this cocktail, as with other monoclonal antibodies, should ONLY be given to patients in the setting of a clinical trial. On a related note, the NEJM is no longer a reliable, trusted source of high-quality clinical information.
Clinical Take Home Point: There is no role for the use of REGN-COV2 outside of a clinical trial. A large, well-done, preferably non-industry sponsored trial is necessary prior to this drug being used outside of this setting."